Wall Street Zen Upgrades Alamar Biosciences (NASDAQ:ALMR) to “Hold”

Alamar Biosciences (NASDAQ:ALMR) was upgraded by Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Alamar Biosciences Trading Up 2.3%

Shares of NASDAQ:ALMR opened at $24.84 on Friday. Alamar Biosciences has a 1-year low of $21.50 and a 1-year high of $25.03.

Insider Activity

In other news, major shareholder Innovation Fund Gp Illumina II acquired 235,294 shares of the company’s stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the insider owned 507,076 shares of the company’s stock, valued at $8,620,292. This trade represents a 86.57% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas Naclerio purchased 235,294 shares of the stock in a transaction dated Monday, April 20th. The stock was bought at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the purchase, the director owned 507,076 shares in the company, valued at $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.